Can Hearts Repair Themselves Via Stem Cells – The Niche
Posted: November 13, 2020 at 8:58 am
Can hearts repair themselves via their own stem cells?
Sometimes what we scientists all know to be true turns out later on to be wrong and there are clear instancesof this in the stem cell field.
For example for decades the dogma was that the adult mammalianbrain did not have stem cells, but now most researchers believethat the adult brain does have stem cells, although for humans this is still being debated.
What we perceive as factual can change over time.
Yamanaka disproved the entrenched notion that differentiated cells were permanently locked into that differentiated state with his revolutionary findings on induced pluripotent stem cells. The new reality, which seemed revolutionary in some ways in 2006-2007, now is established fact.
So what about the idea of the human heart have resident populations of stem cells that can fix problems, perhaps as severe as damage from heart attacks? One of the first stem cell talks I ever saw way back around IPS cells were discovered was by a guy who assumed the factual answer to this question was Yes!
What about now in 2020? I have an ongoing Twitter poll on this question as of Nov. 5, 2020 so check it out below.
Today the cardiac regenerative field finds itself at an interesting crossroads.
A few say yes there are cardiac stem cells and that they can mediate repair. However, most heart researchers that Ive talked to in recent years feel just as strongly that there are no such cells. Some also have added that even if there are at least a handful of such cells or they arise due to damage, they cant do anything meaningful about serious heart damage.
I asked cardiac stem cell expert, Deepak Srivastava for his thoughts on this in a previous post and foundhis answercompelling. Because that was a fairly long time ago, I got an update to the same kind of question just now from two leading cardiac regenerative medicine and stem cell researchers.
Associate Professor of Medicine and Director of Cardiovascular Regenerative Medicine at Mt. Sinai, Hina Chaudhry had this to say:
One thing is certain: As both a clinical cardiologist who has cared for patients with heart attacks and a stem cell biologist, I can tell you that no scientific data supports an endogenous stem cell population in the adult heart and that no adult with a transmural myocardial infarction ever loses the resulting scar throughout their lifetime.
Professor Chuck Murry of the UW sent this:
Our current best evidence suggests that there are no stem cells in the adult heart that can give rise to new cardiomyocytes. This has been studied intensivelyfrom the bottom up, by tracing candidate stem cells and following their differentiated progeny, and from the top down by marking pre-existing cardiomyocytes and looking for their dilution as unmarked stem cells enter the pool. Both have shown the same thing: if this happens at all, its frequency is on the order of 10e-4 per year, which by any measure is next to nothing. There is slow turnover of cardiomyocytes in the adult mammalian heart, at ~1% per year, and this can be accounted for entirely by replication of pre-existing cardiomyocytes. One has to wonder, why has Nature done this? Why would such a vital organ have no stem cells for replenishment, along with such a low rate of endogenous replication?
I believe that Drs. Murry and Chaudhry are right. Chucks last question there is one for long discussions and is similar to discussions Ive had about the few stem cells/potential for endogenous repair in the adult human brain.
Still, you can find a diversity of papers now in 2020 in PubMed with Heart Regeneration or Cardiac Regeneration or Cardiac stem cells in their titles. However, many of the papers relate to stem cell infusions rather than invoking endogenous resident cells.
If not in humans, what about other mammals? There are glimpses of interesting possible stem cell activity in the mammalian heart, even if not in humans
A November 2014Cell Stem Cell paper from the lab of Juan Carlos Izpisua Belmonte, entitled InVivo Activation of a Conserved MicroRNA Program Induces Mammalian Heart Regeneration, argues for endogenous mammalian heart regeneration in part via dedifferentiation of cells into stem-like cells. This raises the interesting notion that while the mammalian heart does not normally have many (or any?) resident stem cells, damage can change some other cells into stem cell-like cells.
One of the biggest advocates of endogenous cardiac stem cells and repair, Piero Anversa formerly of Harvard and Brigham and Womens Hospital, has become one of the most controversial as well. His papers have come under fire and some have been retracted. Anversa was the subject of a Harvard investigation and was suing Harvard for how it has conducted the investigation and other matters related to his work.
In my view, his situation has raised even more skepticism about the idea of endogenous heart stem cells in people.
Even if the endogenous stem cell-like activity in the heart is absent or not enough to mediate clinically significant repair in humans, by deciphering the molecular basis of this kind of activity in other animals could the field still open the door to powerful new treatments for heart disease? For instance, if some adult mammalian hearts naturally replace 1 in 200 cells per year, perhaps cardiac researchers can find a way to boost that by an order of magnitude with a drug and have a meaningful impact for human patients.
Or if dedifferentiation of non-stem cells in the heart into stem cell-like cells can be induced by damage, could a drug therapy trigger that same effect even if damage occurred long ago or in the context of relatively minor damage?
Many researchers are focusing more on using injections of stem cells into the heart to repair damage. The types of stem cells being used for research attempts at heart repair are very diverse, including both placental cells and indirect use of IPS cells in Japan via a recently approved trial there.
Even the area of stem cell transplants into the heart generates its share of debate and well have to see in the long run how the clinical trial data turn out. I hope there can be positive impact in the future given the overwhelming number of people with heart damage.
Related
Read more:
Can Hearts Repair Themselves Via Stem Cells - The Niche
- Worldwide Industry for Biopreservation to 2026 - Key Drivers, Restraints and Opportunities - Yahoo Finance - January 5th, 2021
- Vape Flavorings Are Cardiotoxic and Can Damage the Heart - SciTechDaily - December 28th, 2020
- Outlook on the Biopreservation Global Market to 2026 - Profiling Avantor, BioLife Solutions and ThermoGenesis Among Others - GlobeNewswire - December 26th, 2020
- UC Davis researchers find a way to help stem cells work ... - December 17th, 2020
- I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire - December 17th, 2020
- Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all - Study Finds - December 17th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 17th, 2020
- Network of Genes Involved in Congenital Heart Disease Identified - Technology Networks - December 17th, 2020
- Industry News: Hamamatsu Photonics UK Ltd and the Medical Technologies Innovation Facility enter into a partnership agreement - SelectScience - December 17th, 2020
- Osteoporosis treatments could be on the way after scientists identify aging gene - iNews - November 30th, 2020
- Global Myocardial Infarction Drug Market to have sustainable growth over the forecast period 2020-2028| Leading Players BioCardia, Inc., Laboratoires... - November 30th, 2020
- Breakthroughs in Stem Cell Based Treatment of Heart Disease - The Connecticut College Voice - November 24th, 2020
- Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack - Cath Lab Digest - November 24th, 2020
- Autologous Stem Cell Based Therapies Market Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026 - PRnews Leader - November 24th, 2020
- 3D Cardiac Mapping Systems Market Competitive Landscape Analysis with Forecast by 2028 - The Haitian-Caribbean News Network - November 24th, 2020
- Organoids mimic the early development of the heart in mouse embryos - BioNews - November 18th, 2020
- Mimicking the early development of the heart - Tech Explorist - November 18th, 2020
- Cell Therapy and Gene Therapy Markets, 2019-2020 & Forecast to 2025 and 2030 - ResearchAndMarkets.com - Business Wire - November 18th, 2020
- UPDATED: Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq? - Endpoints News - November 18th, 2020
- Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs ... - November 13th, 2020
- Global Autologous Stem Cell Based Therapies Market 2020 Segmentation, Statistics, Top Manufacturers, Regional Analysis and Forecast to 2025 - The... - November 13th, 2020
- The Amniotic Fluid Stem Cell Therapy market to be in conjunction to growth from 2018 to 2026 - PRnews Leader - November 13th, 2020
- BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights - GlobeNewswire - November 13th, 2020
- Exploring Genetic Variation and COVID-19 Clinical Variability - Technology Networks - November 13th, 2020
- Autologous Stem Cell Based Therapies Market 2020 Emerging Trend and Advancement - News by aeresearch - November 10th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 10th, 2020
- Global Progenitor Cell Product Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2026 - Zenit News - November 10th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients... - November 10th, 2020
- Advancement: Know the Rapid Growth Factors of Biopreservation Market| Stay Up-To-Date With Emerging - PharmiWeb.com - November 10th, 2020
- Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader - November 4th, 2020
- California Prop 14 would keep taxpayer funding of stem cell therapy research, which can change lives: Meet the Langenhop kids - AZCentral.com - November 4th, 2020
- Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition - Business Wire - November 4th, 2020
- Stem Cell Therapy Market to Surge at a Robust Pace in Terms of Revenue Over2017 2025 - Royal Sutton News - November 4th, 2020
- Autologous Stem Cell Based Therapies Market to Witness Increase in Revenues by 2020-2026 - PRnews Leader - November 3rd, 2020
- Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease - PRNewswire - November 3rd, 2020
- Ready To Use Autologous Stem Cell Based Therapies Market Industry Analysis, Trend and Growth, 2020-2020 - Royal Sutton News - November 1st, 2020
- Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - GlobeNewswire - November 1st, 2020
- Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 - The Think Curiouser - November 1st, 2020
- The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients - DocWire News - October 23rd, 2020
- COVID-19 can affect the heart - Science Magazine - October 23rd, 2020
- Stem Cell Assay Market expected to Witness a Sustainable Growth over 2025 - TechnoWeekly - October 23rd, 2020
- Exosome Therapeutic Market 2020-2026 Demand Analysis and Projected Huge Growth by Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,... - October 23rd, 2020
- Stem Cell Assay Market In-Depth Analysis & Forecast 2017-2025 - The Think Curiouser - October 22nd, 2020
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West - October 22nd, 2020
- Exosome Therapeutic Market 2020-2026 to Witness Excellent Growth || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,... - October 22nd, 2020
- Banking wisdom: Teen saving stem cells in hopes of future treatment - LubbockOnline.com - October 16th, 2020
- Global Cell Based Assay & High Content Screening Markets to 2024: Updated Report - Understand Growth Expectations and the Potential Market Size -... - October 16th, 2020
- Merck Presents Three-Year Survival Data for KEYTRUDA (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational... - October 16th, 2020
- Preclinical Study Shows Improvement In Recovery From Heart Attack With Exosomes - Anti Aging News - October 10th, 2020
- Autologous Stem Cell Based Therapies Market Size, Business Revenue Forecast, Leading Competitors And Growth Trends 2026| Regeneus, Mesoblast,... - October 10th, 2020
- Recording thousands of nerve cell impulses at high resolution - Newswise - October 4th, 2020
- Wisconsin Medicine Livestream: The future of medicine - Wisbusiness.com - October 2nd, 2020
- Measuring chips amplify and record nerve cells - Futurity: Research News - October 2nd, 2020
- Recording thousands of nerve cell impulses at high resolution - ScienceDaily - Up News Info - October 2nd, 2020
- Kyoto University project aims to supply iPS cells widely at low cost - The Japan Times - September 30th, 2020
- Heart attack patches may save lives in US and beyond - Galveston County Daily News - September 30th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2025 Global Briefing, Growth Analysis And Opportunities Outlook | Major Giants ... - September 30th, 2020
- Exosome Therapeutic Market Latest Industry Size, Growth, Share, Emerging Demands, and Competitive Landscape || Major Gaints Jazz Pharmaceuticals,... - September 30th, 2020
- James T. Willerson, Revered Clinician, Editor, and Mentor, Dies at 81 - TCTMD - September 22nd, 2020
- Researchers Discover a Way To Create Induced Tropoblast Stem Cells - Technology Networks - September 18th, 2020
- What Is Covid-19 Doing to Our Hearts? - The New Republic - September 18th, 2020
- Astellas and Seattle Genetics Announce PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated... - September 18th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - BioSpace - September 14th, 2020
- David Shavelle, MD, Named Medical Director of Adult Cardiology for the MemorialCare Heart & Vascular Institute at Long Beach Medical Center -... - September 14th, 2020
- Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace - September 14th, 2020
- How the coronavirus causes 'carnage' in the heart - The Daily Briefing - September 9th, 2020
- Innovative treatments for heart failure - Open Access Government - September 9th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Scope And Price Analysis 2020 | Major Giants Fibrocell, Genesis Biopharma, Georgia... - September 9th, 2020
- Microengineered 3D pulmonary interstitial mimetics highlight a critical role for matrix degradation in myofibroblast differentiation - Science... - September 9th, 2020
- COVID-19 Drug Discovery and Development Why Diverse Strategies Are Critical - Technology Networks - September 9th, 2020
- Much-loved son Joe Brown saved three lives after tragic death at just 29 - Birmingham Live - September 9th, 2020
- Market Growth of Global Stem Cells to Remain Sluggish through 2020 2030 - The News Brok - September 4th, 2020
- Global and Asia Pacific Progenitor Cell Product Market to Witness Huge Growth by 2027 Major Manufacturers included in report NeuroNova AB, StemCells,... - September 4th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2025 | Major Giants Fibrocell, Genesis Biopharma, Georgia Health Sciences... - August 29th, 2020
- Keio University gets OK for iPS-based heart cell transplant plan - The Japan Times - August 29th, 2020
- Scientists grow the first functioning mini human heart model - MSUToday - August 22nd, 2020
- First lab-made 'mini-hearts' mimic the real thing - Futurity: Research News - August 22nd, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With... - August 19th, 2020
- Exosome Therapeutic Market (Covid 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 -... - August 19th, 2020
- Stem Cell Therapy Market Landscape Assessment By Type and Analysis Current Trends by Forecast To 2025 - The Daily Chronicle - August 17th, 2020